Literature DB >> 6916710

The activation of the alternative pathway C3 convertase by human plasma kallikrein.

R G DiScipio.   

Abstract

Human plasma kallikrein can replace factor D for the activation of the alternative pathway C3 convertase of human complement. The factor B cleavage patterns by factor D and kallikrein are indistinguishable. The ability of kallikrein to cleave factor B is influenced by the magnesium ion concentration and the C3b concentration. Factor D is about ten-fold more effective on a molar basis, for the alternative pathway C3 convertase activation than is kallikrein. The physiological role of the action of kallikrein on the alternative pathway C3 convertase is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6916710      PMCID: PMC1555245     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

1.  Factor D in the alternate pathway of complement activation: purification, physicochemical characterization and functional role.

Authors:  M P Dierich; U Hadding; W König; M Limbert; H U Schorlemmer; D Bitter-Suermann
Journal:  Immunochemistry       Date:  1974-09

2.  Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.

Authors:  V Brade; A Nicholson; D Bitter-Suermann; U Hadding
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

3.  The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics.

Authors:  V Brade; A Nicholson; G D Lee; M M Mayer
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

4.  Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads.

Authors:  P Cuatrecasas
Journal:  J Biol Chem       Date:  1970-06       Impact factor: 5.157

5.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

6.  Characterization of human, bovine, and horse antithrombin III.

Authors:  K Kurachi; G Schmer; M A Hermodson; D C Teller; E W Davie
Journal:  Biochemistry       Date:  1976-01-27       Impact factor: 3.162

7.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

8.  A simple two-step isolation procedure for human and bovine antithrombin II/III (heparin cofactor): a comparison of two methods.

Authors:  E Thaler; G Schmer
Journal:  Br J Haematol       Date:  1975-10       Impact factor: 6.998

9.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

10.  Prekallikrein deficiency in man.

Authors:  K D Wuepper
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  38 in total

1.  A case of atypical hemolytic uremic syndrome due to anti-factor H antibody in a patient presenting with a factor XII deficiency identified two novel mutations.

Authors:  Eiji Matsukuma; Yoshimitsu Gotoh; Yoshiyuki Kuroyanagi; Takuji Yamada; Mitsuji Iwasa; Satoshi Yamakawa; Takuhito Nagai; Nobuaki Takagi; Hiromu Mae; Kenji Iijima; Elena Bresin
Journal:  Clin Exp Nephrol       Date:  2011-01-27       Impact factor: 2.801

2.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

3.  Induction of complement C3a receptor responses by kallikrein-related peptidase 14.

Authors:  Katerina Oikonomopoulou; Robert A DeAngelis; Hui Chen; Eleftherios P Diamandis; Morley D Hollenberg; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

4.  2013 scientific sessions Sol Sherry distinguished lecture in thrombosis: polyphosphate: a novel modulator of hemostasis and thrombosis.

Authors:  Stephanie A Smith; James H Morrissey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-23       Impact factor: 8.311

Review 5.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

Review 6.  The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis.

Authors:  R W Colman; R B Sartor; A A Adam; R A DeLa Cadena; A Stadnicki
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

7.  The acute phase response of C3, C5, ceruloplasmin, and C-reactive protein induced by turpentine pleurisy in the rabbit.

Authors:  P C Giclas; U Manthei; R C Strunk
Journal:  Am J Pathol       Date:  1985-07       Impact factor: 4.307

Review 8.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

9.  Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins.

Authors:  Boyangzi Li; Jiraporn Suwan; Jeffrey G Martin; Fuming Zhang; Zhenqing Zhang; Debra Hoppensteadt; Melanie Clark; Jawed Fareed; Robert J Linhardt
Journal:  Biochem Pharmacol       Date:  2009-04-21       Impact factor: 5.858

10.  Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation.

Authors:  My-Linh Ngo; Fakhri Mahdi; Dhaval Kolte; Zia Shariat-Madar
Journal:  J Inflamm (Lond)       Date:  2009-01-27       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.